Our Posts

The opioid crisis has led to a significant increase in neonatal abstinence syndrome (NAS), with an opioid-addicted baby born every 15 minutes. These infants suffer from withdrawal symptoms and long-term health issues. Parker Waichman LLP is investigating lawsuits against pharmaceutical companies for their role in this epidemic. While mothers are often blamed, many were prescribed opioids by doctors. Legal claims focus on deceptive practices by drug manufacturers. Parker Waichman LLP offers consultations to affected families, aiming to hold these companies accountable.

A recent study presented at the Digestive Disease Week conference highlights the risk of hypomagnesemia, a condition of low magnesium levels, associated with the use of proton pump inhibitors (PPIs). The FDA had previously issued a warning about this risk, noting that hypomagnesemia can lead to serious health issues if untreated. The study, involving 1,317 patients, found that PPI users had a significantly higher risk of low magnesium levels compared to non-users. The FDA recommends monitoring magnesium levels in patients starting PPI treatment, especially those on other medications that may cause hypomagnesemia.

Parker Waichman LLP is handling lawsuits related to cybersecurity vulnerabilities in St. Jude/Abbott cardiac devices, such as pacemakers and defibrillators. These devices are at risk of cyber-attacks, potentially leading to serious patient harm. The FDA has issued recalls due to these vulnerabilities, and affected patients may be entitled to compensation. If you suspect your device has been compromised, contact Parker Waichman LLP for a free consultation to explore your legal options and protect your rights.

The FDA has warned that proton pump inhibitors (PPIs) may increase the risk of developing Clostridium difficile–associated diarrhea (CDAD), a serious condition. CDAD is a persistent type of diarrhea caused by the C. diff bacterium, often spread in healthcare settings. The FDA advises healthcare providers to consider CDAD in PPI users with unresolved diarrhea and to prescribe the lowest effective PPI dose. Patients should seek immediate medical attention if they experience persistent watery stool, abdominal pain, and fever while on PPIs. PPIs are used to treat conditions like GERD and are available both by prescription and over-the-counter.

Researchers at Brigham and Women's Hospital found that SGLT2 inhibitors, a class of drugs for type 2 diabetes, are linked to a higher risk of diabetic ketoacidosis (DKA), a serious condition. The study, using data from 2013-2014, compared SGLT2 inhibitors with DPP4 inhibitors, which do not have this risk. Results showed that SGLT2 users had about twice the risk of DKA. The FDA had already warned about this risk in 2015. Legal actions have been taken against manufacturers for allegedly concealing these risks.

A recent study in Orthopedics highlights the dangers of metal-on-metal hip implants, focusing on aseptic acetabular loosening, metallosis, and pseudotumor formation. The study reviewed 80 patients who underwent revision surgeries, with 56% due to aseptic loosening. Most affected patients had Zimmer’s Durom Cup or DePuy ASR cups. Other failure causes included infection and metal hypersensitivity. Significant metallosis was found in 10 patients, primarily with DePuy ASR cups. The study emphasizes the need for close monitoring of patients with these implants.

Prevacid and Prevacid 24 Hour are proton pump inhibitors used to treat gastrointestinal issues like severe heartburn. Despite their widespread use, manufacturers have not adequately informed the public about the risks of long-term use, which can lead to serious health issues such as kidney disease and stomach cancer. Common side effects include headaches and abdominal pain, but more severe effects like kidney injuries and low magnesium levels have been reported. Legal actions are being pursued against the manufacturers for failing to warn consumers about these risks.

The Bair Hugger lawsuits involve claims that the forced-air warming blanket used during surgeries causes deep joint infections by introducing contaminants into surgical sites. As of October 2016, 809 cases are consolidated in a federal multidistrict litigation (MDL) in Minnesota. The litigation, which began with 14 cases in December 2015, has grown significantly. Bellwether trials are set to start in November 2017. The lawsuits allege that 3M and Arizant Healthcare failed to warn about the infection risks associated with the device.

Pradaxa, a blood-thinning medication approved in 2010, has been linked to serious bleeding side effects, including internal bleeding, gastrointestinal and cerebral hemorrhaging, and death. By late 2011, 260 deaths were reported worldwide due to these side effects. Unlike warfarin, Pradaxa has no antidote, making its bleeding events more dangerous. Parker Waichman LLP is investigating these cases and offers free consultations for those affected. Legal action may provide compensation for medical expenses and other damages.

Parker Waichman LLP, a national plaintiffs' law firm, is investigating claims related to the diabetes medication Synjardy, which combines empagliflozin and metformin. Synjardy has been linked to an increased risk of lower extremity amputations. The firm alleges that Boehringer Ingelheim, the manufacturer, failed to adequately warn about these risks. Parker Waichman is seeking justice and financial compensation for affected individuals, leveraging their extensive experience in challenging large pharmaceutical companies. They offer free case evaluations for those impacted by Synjardy.

Parker Waichman LLP, a national law firm, is reviewing cases against pharmaceutical companies involved in the opioid crisis. They aim to hold these companies accountable for the social and economic impacts of their actions. The firm urges potential clients to act quickly to preserve their legal rights. Individuals are encouraged to contact them at 1-800-YOURLAWYER or fill out a consultation form to discuss their legal options with an experienced opioid lawyer.

Patients who took Xarelto, a powerful anticoagulant, have filed lawsuits due to severe internal bleeding and fatalities. Jointly developed by Johnson & Johnson and Bayer, Xarelto has been linked to life-threatening side effects. Parker Waichman LLP, known for its dedication to injured clients, has recovered over $2 billion in compensation. The firm offers free case reviews for those affected by Xarelto, emphasizing their commitment to fighting against negligent pharmaceutical companies.

A report from *Health Imaging* highlights concerns about MRI contrast agents, particularly gadolinium-based contrast agents (GBCAs), which may remain in the body for extended periods. The FDA has identified health risks for patients with kidney failure, linking certain GBCAs to nephrogenic systemic fibrosis (NSF), a serious condition. In response, the FDA has mandated additional testing and warnings, while the European Medicines Agency has recommended suspending some linear GBCAs. Studies show linear GBCAs have higher gadolinium retention compared to macrocyclic GBCAs. Legal assistance is available for affected individuals.

Parker Waichman LLP has filed a lawsuit on behalf of an Indiana woman who suffered permanent injuries allegedly due to the Mirena IUD. The lawsuit, filed in New Jersey Superior Court, names Bayer Corporation and Berlex Laboratories as defendants. The complaint alleges that the Mirena IUD, approved by the FDA in 2000, can migrate spontaneously, a risk not adequately warned about on its label. The plaintiff underwent surgery to remove the IUD after it was found in her abdominal wall. The lawsuit claims the defendants overstated the device's benefits and understated its risks.

Johnson & Johnson is facing numerous lawsuits alleging that its talcum powder products, such as Baby Powder and Shower-to-Shower, have caused ovarian cancer in women who used them regularly. These cases are part of a multidistrict litigation in the U.S. District Court, District of New Jersey, overseen by Judge Freda L. Wolfson. The lawsuits claim J&J ignored research linking talc to cancer since the 1970s. Some trials have already resulted in significant damages awarded to plaintiffs. Talc, often mined near asbestos, is used in cosmetics and is not FDA-regulated.

The diabetes drug Invokana, containing canagliflozin, is linked to a higher risk of amputations, primarily affecting toes, feet, and lower legs. The FDA has issued a Black Box Warning due to studies showing increased amputation rates among users compared to those on a placebo. Invokana is used to manage blood sugar in type 2 diabetes but may lead to dehydration, reducing blood flow to limbs and causing complications. Despite these risks, it remains prescribed, with patients advised to monitor for symptoms and consult healthcare providers.

To ensure comprehensive compensation for a Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor amputation lawsuit, gather all relevant medical records and evidence linking the medication to the injury. Consult with a specialized attorney experienced in pharmaceutical litigation to evaluate your case. Document all related expenses, including medical bills and lost wages, to support your claim. Stay informed about legal proceedings and settlement options. Act promptly, as there may be time limits for filing a lawsuit.

Parker Waichman LLP is accepting cases related to the Zimmer Biomet Comprehensive Reverse Shoulder System, which has been recalled due to high fracture rates. The FDA issued a CLASS I Recall in 2016, affecting over 3,600 units. Patients with these implants may face severe complications, including revision surgeries and permanent loss of shoulder function. Parker Waichman LLP is pursuing litigation against Zimmer Biomet for alleged failures in testing, design, and manufacturing. They offer free consultations to help affected individuals explore their legal options and seek justice.

Proton pump inhibitors (PPIs), such as Prevacid, Nexium, and Prilosec, are used to treat heartburn and acid reflux by reducing stomach acid production. However, studies have linked long-term PPI use to increased risks of kidney disease, including chronic kidney disease (CKD) and acute kidney injury. Lawsuits have been filed against PPI manufacturers, alleging failure to warn about these risks. The U.S. Judicial Panel on Multidistrict Litigation is considering consolidating these cases to streamline proceedings. Legal firms are actively seeking individuals affected by PPI-related kidney injuries for potential claims.

Parker Waichman LLP offers a free case evaluation for individuals affected by IVC filters. Their experienced legal team is committed to fighting for clients to prevent financial burdens from injuries and losses. Prompt action is crucial to protect your rights. Contact them at 1-800-YOURLAWYER (1-800-968-7529) or complete the consultation form to have an IVC Filter Lawyer discuss your rights and claim options.

The FDA is proposing a study to assess if doctors and consumers can identify misleading drug advertisements, aiming to ensure truthful and useful information is provided. Critics argue the FDA's enforcement of advertising rules has weakened, with fewer warning letters issued and no fines since 2007. Misleading ads can lead to product liability lawsuits if consumers are harmed. Such lawsuits require proving the product was used as intended, was defective, and caused injury. Damages may include medical costs, lost wages, and more. Legal advice is recommended for pursuing claims.

The national opioid epidemic has escalated into a significant crisis, prompting legislative and law enforcement actions to address its impact. Efforts include increased funding for treatment and new enforcement policies targeting fraudulent distribution. The crisis has led to numerous lawsuits against pharmaceutical companies, holding them accountable for misleading marketing and distribution practices. The economic burden of opioid abuse is substantial, with costs reaching $78.5 billion annually. States like Ohio and West Virginia are particularly affected, with high overdose rates prompting legal actions to recover public costs from drug manufacturers.

Xarelto, an anticoagulant used to prevent blood clots in patients undergoing knee or hip replacement surgery, has been linked to serious, disabling, or fatal injuries, including blood clots and thromboembolic events. The Institute for Safe Medication Practices (ISMP) reported that Xarelto had the highest number of adverse events in the first quarter of 2012, with 356 cases, primarily involving severe blood clots in younger patients. Legal firms are investigating potential lawsuits for those affected by Xarelto's side effects.

Rhode Island's US District Court is handling numerous lawsuits related to the defective Kugel Mesh Hernia Patch, following a 2005 recall by Davol, Inc. The Judicial Panel on Multidistrict Litigation has consolidated these cases, transferring them to Rhode Island for pretrial proceedings. The patch, intended to alleviate hernia pain, was recalled due to issues with its recoil ring, causing serious injuries. Davol is accused of delaying the recall despite early complaints. The court will assess Davol's negligence in addressing the patch's defects.